Plain-English translation of NCT07233239 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing whether cannabidiol oral solution (), a liquid medication you take by mouth, can help reduce focal seizures when added to your current seizure medications. Researchers want to see if the medication is safe and how well it works in people whose seizures start in one part of the brain. The study will also look at how your brain responds to the treatment using special brain scans and thinking tests.
Many people with focal seizures continue to have breakthrough seizures even while taking one or more seizure medications. This trial is exploring whether this new treatment could help reduce seizure frequency and improve quality of life for people whose seizures are not fully controlled by existing medications.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you will receive the new oral medication to take along with your current seizure medicines. You'll visit the research center for check-ups where doctors will monitor how often you have seizures, check for side effects, and run blood tests. Some participants will also have optional brain imaging scans (fMRI) and thinking tests to help researchers understand how the medication works. The study will track how you respond to the treatment over time and collect information about how the medication affects your daily life and well-being.
AI-generated summary from trial data ยท Aug 29, 2026 ยท Not medical advice
United States